Randomized Controlled Trial
Copyright ©The Author(s) 2016.
World J Transplant. Jun 24, 2016; 6(2): 429-436
Published online Jun 24, 2016. doi: 10.5500/wjt.v6.i2.429
Table 1 Demographic and baseline characteristics of the patients
FeaturesControl (n = 23)Intervention (n = 14)P
Male/female18 (78.3%)/5 (21.7%)11 (78.6%)/3 (21.4%)1.00
Age (yr)55.4 ± 9.955.8 ± 5.40.97
BMI (kg/m2)27.3 ± 4.528.6 ± 5.40.58
Diagnosis
HCV5 (21.7%)4 (28.6%)
HCC + HCV4 (17.4%)
Alcohol3 (13%)3 (21.4%)
HCC3 (13%)
Alcohol + HCV3 (13%)2 (14.2%)
Alcohol + HCC1 (4.3%)
Alcohol + HCV + HCC1 (4.3%)2 (14.2%)
Autoimmune hepatitis1 (4.3%)
Polycystic liver disease1 (4.3%)
Cryptogenic cirrhosis1 (7.1%)
Sclerosing cholangitis1 (7.1%)
HBV + HCV1 (7.1%)
Table 2 Comparison between the control and intervention groups
Control (n = 23)
Intervention (n = 14)
P
InitialFinalInitialFinal
MIP (cmH2O)88.5 (44.1)98.3 (39.2)101.1 (34.4)117.9 (43)0.45
MEP (cmH2O)108.3 (46.3)116.5 (51.8)113.6 (31)128.2 (35)0.61
EMG rectus (μV)52.9 (51.1)46.1 (29.7)32.5 (12.4)28.8 (7.9)0.65
EMG diaphragm (μV)43.8 (14.9)53.8 (22.4)55.7 (34.7)35.6 (15.8)0.0011
FVC (%)84.6 (13.9)85.5 (16.1)88.3 (14.5)92.6 (14.2)0.42
FEV1 (%)84.6 (15.1)85.4 (14.5)88.6 (20)90 (14.1)0.5
FEF25%-75% (%)92.4 (31.2)94.7 (24.6)100.7 (47.1)102.9 (44.2)0.72
Funcional capacity68.5 (24.5)71.7 (21.7)69.3 (21.4)84.6 (14.5)0.0062
Physical role52.2 (39.1)45.7 (38.9)60.7 (38.9)55.4 (38.2)0.92
Pain61 (32)61.3 (21.1)62 (27.9)56.7 (30.1)0.78
General health52.8 (26.2)58.4 (26.3)59.3 (20.1)68.4 (19.3)0.4
Vitality61.7 (23.9)59.8 (23.2)58.9 (15.2)65 (25.2)0.33
Social aspects58.2 (34.9)67.9 (29.9)68.8 (37.3)75.9 (30)0.93
Emotional role60.8 (39.8)56.5 (44.3)45.1 (44.5)61.9 (36.6)0.16
Mental health59.1 (26.4)64.5 (24)64.9 (20.7)78.3 (22)0.14